PlainPharmaWatch

CMS Open Payments · Program Year 2024

BioCryst US Sales Co., LLC

BioCryst US Sales Co., LLC reported $658,195.86 in payments to 6,409 physicians and teaching hospitals across 6,409 transactions.

See the rankings → How this is sourced
$658.2K
Total payments
6,409
Transactions
6,409
Recipients
−$10.0K
General Payments vs PY2023

BioCryst US Sales Co., LLC reported $658,195.86 in payments to 6,409 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #705 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $102.70 per recipient across 7 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

BioCryst US Sales Co., LLC pairs above-median payment volume with an unusually diversified payment pattern across a wide recipient base.

#705
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
7
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

BioCryst US Sales Co., LLC's CMS-reported General Payments decreased by $10.0K (−1.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: BIOCRYST US SALES CO., LLCPY2023: BIOCRYST US SALES CO., LLCPY2024: BioCryst US Sales Co., LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$668.2KPY2024$658.2K
PY2023
$668,158.53
PY2024
$658,195.86

How BioCryst US Sales Co., LLC ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

BioCryst US Sales Co., LLC's total vs. every reporting company

CMS Open Payments, Program Year 2024

$658,196 Top 37% higher than 63% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). This entry sits in this band. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for BioCryst US Sales Co., LLC

$658,195.86: that is what BioCryst US Sales Co., LLC reported in payments to 6,409 physicians and teaching hospitals during Program Year 2024, spread across 6,409 transactions ($102.70 per transaction, $102.70 per recipient). The company sits at rank #705 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 7 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $294.9K across 86 transactions, 44.8% of the company's reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

BioCryst US Sales Co., LLC made 7 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $294.9K, 44.8% of the company's reported total.

How BioCryst US Sales Co., LLC divides its payments

Ranked by total dollars reported per category

1. Compensation for Services…$294.9K2. Food and Beverage$155.8K3. Consulting Fee$118.3K4. Travel and Lodging$49.7K5. Grant$29.7K6. Space Rental or Facility …$9.1K7. Education$607.99
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $294.9K 86
Food and Beverage $155.8K 6,115
Consulting Fee $118.3K 33
Travel and Lodging $49.7K 117
Grant $29.7K 3
Space Rental or Facility Fees $9.1K 6
Education $607.99 49

Recipient Concentration in General Payments

The five largest recipient relationships account for $234,293.91 (35.6%) of $658,195.86 in this company's General Payments records across 2,052 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for BioCryst US Sales Co., LLC

The five named recipients with the highest reported General Payments from this company

Raffi Tachdjian$68.4KWilliam Lumry$62.6KPatricia Stewart$49.7KJeffrey Rumbyrt$27.5KDonald Levy$26.1K
  1. 1

    Raffi Tachdjian

    $68,423.21 across 58 reported transactions

  2. 2

    William Lumry

    $62,597.33 across 32 reported transactions

  3. 3

    Patricia Stewart

    $49,671.68 across 41 reported transactions

  4. 4

    Jeffrey Rumbyrt

    $27,480.38 across 31 reported transactions

  5. 5

    Donald Levy

    $26,121.31 across 34 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $102.70. Average per recipient: $102.70.

Total Amount

$658,195.86

Avg per Transaction

$102.70

Avg per Recipient

$102.70

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

BioCryst US Sales Co., LLC Share

0.0%

#705 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to BioCryst US Sales Co., LLC

Xtant Medical Inc

$659.3K 454 recipients

Enterra Medical, Inc.

$656.0K 1,810 recipients

Fusion Orthopedics USA, LLC

$655.1K 780 recipients

Seigla Medical, Inc.

$651.1K 12 recipients

Vascular Graft Solutions Inc

$668.1K 2 recipients

Novo Nordisk Health Care AG

$647.6K 208 recipients

Frequently Asked Questions

How much did BioCryst US Sales Co., LLC pay to physicians and hospitals in 2024? ▾
BioCryst US Sales Co., LLC made $658,195.86 in payments to physicians and hospitals in Program Year 2024, across 6,409 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from BioCryst US Sales Co., LLC? ▾
Averaging $102.70 per recipient, BioCryst US Sales Co., LLC's 2024 payments reached 6,409 physicians and teaching hospitals.
What types of payments did BioCryst US Sales Co., LLC make? ▾
General payments from BioCryst US Sales Co., LLC span 7 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Compensation for Services Other Than Consulting" at $294.9K, representing 44.8% of the company's reported total.
How does BioCryst US Sales Co., LLC rank among pharmaceutical companies? ▾
BioCryst US Sales Co., LLC ranks #705 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from BioCryst US Sales Co., LLC? ▾
The average transaction from BioCryst US Sales Co., LLC was $102.70 in 2024. The company made 6,409 total transactions to 6,409 recipients.
Where does the payment data for BioCryst US Sales Co., LLC come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download BioCryst US Sales Co., LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.